This report was first published by Endpoints News. To see the original version, click here
Ever since Chris Viehbacher arrived at Biogen in 2022, investors have been wondering how he planned to turn around the biotech.
On Tuesday, they got at least part of their answer. The company’s $5.6 billion deal for Apellis is the clearest signal yet for how Viehbacher is positioning Biogen for growth after the disappointing launch of its Alzheimer’s drug and continued questions about its pipeline.
您已阅读15%（490字），剩余85%（2773字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。